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ABSTRACT:
The biological processes controlling human growth are diverse, complex and poorly 
understood. Genetic factors are important and human height has been shown to be 
a highly polygenic trait to which common and rare genetic variation contributes. 
Weaver syndrome is a human overgrowth condition characterised by tall stature, 
dysmorphic facial features, learning disability and variable additional features. We 
performed exome sequencing in four individuals with Weaver syndrome, identifying 
a mutation in the histone methyltransferase, EZH2, in each case. Sequencing of 
EZH2 in additional individuals with overgrowth identified a further 15 mutations. 
The EZH2 mutation spectrum in Weaver syndrome shows considerable overlap with 
the inactivating somatic EZH2 mutations recently reported in myeloid malignancies. 
Our data establish EZH2 mutations as the cause of Weaver syndrome and provide 
further links between histone modifications and regulation of human growth.
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INTRODUCTION
The control of human growth is a complex process 
involving multiple different biological pathways. 
Several conditions associated with human overgrowth 
are recognised and the underlying causes are extremely 
diverse [6]. More recently, GWAS studies have identified 
over 180 loci that contribute to human height, some of 
which overlap with Mendelian syndromes [1]. Weaver 
syndrome was first described in 1974 and is characterised 
by pre and postnatal overgrowth, variable learning 
disability and a distinctive facial appearance [2, 3]. The 
majority of cases are sporadic, though rare familial cases 
exhibiting an autosomal dominant pattern of inheritance 
have been reported [7-9]. Here we have undertaken exome 
sequencing and sanger sequencing to identify the cause of 
Weaver syndrome and to characterise the molecular and 
clinical associations of the causative gene.
RESULTS
To identify the cause of Weaver syndrome we 
first undertook exome capture and sequencing in four 
individuals with classic features of the condition, using 
the Agilent SureSelect Human All Exon kits and Illumina 
GAIIx platform (cases 3, 10, 14 and 16, Table 1). We 
used NextGENe software to detect sequence variants 
as previously described [10]. To prioritise variants for 
consideration we first evaluated only variants with 
coverage of at least 15 reads and we excluded variants 
that were intronic, synonymous, recorded in dbSNP and/
or were present in 45 exomes we performed in other 
conditions. After these filters, 1,357 variants remained. We 
applied a script to ascertain genes with variants in all four 
individuals. This identified only one gene, EZH2, with 
each case carrying a different EZH2 mutation (Table 1). 
We confirmed the four mutations by Sanger sequencing 
and also showed that the mutations were not present in the 
seven parental samples available for study, establishing 
that the mutations had arisen de novo in at least three of 
the individuals with Weaver syndrome. 
To further evaluate the role of EZH2 in human 
overgrowth conditions we sequenced the full coding 
sequence and intron-exon boundaries of the gene by 
Sanger sequencing in an additional 300 individuals 
(Supplementary Table 1). These cases either had a 
clinical diagnosis of Weaver syndrome, or a non-specific 
overgrowth syndrome which we defined as height and/or 
head circumference at least two standard deviations above 
the mean, together with variable additional phenotypic 
features. 
We identified mutations that we consider pathogenic 
in a further 15 individuals (Table 1, Figure 1, Figure 2, 
Supplementary Table 2). For nine individuals, analysis of 
parental samples demonstrated that the relevant mutation 
had arisen de novo, confirming pathogenicity. Case 2 had a 
family history of overgrowth and there was full segregation 
of the EZH2 mutation, K156E, with the overgrowth 
Case ID Mutation; protein alteration Inheritance
Heighta
(SD)
OFCa
(SD)
Learning 
disability
Malignancy
1 c.401T>C;p.M134T de novo +2.2 +0.3 mild
2 c.466A>G;p.K156E familial +3.3 +1.5 mild
3 c.836A>G;p.H279R de novo +2.6 +2.3 mild
4 c.1876G>A;p.V626M de novo +3.6 +3.2 no
5 c.1915A>G;p.K639E de novo +6 +4.9 moderate
6 c.1987T>A;p.Y663N de novo +5 +3 mild
7 c.1991A>T;p.D664V nk +3.8 +3.2 moderate
8 c.2044G>A;p.A682T de novo +4.2 +1.8 mild Neuroblastoma, ALL
9 c.2050C>T;p.R684C de novo +2.9 nk mild
10 c.2050C>T;p.R684C nk +3.5 +1.5 nk
11 c.2050C>T;p.R684C de novo +3 +2.6 mild
12 c.2050C>T;p.R684C nk +5.6 +1.7 mild
13 c.2084C>T;p.S695L de novo +5 nk mild
14 c.2199C>G;p.Y733X de novo +7.6 +2.7 no
15 c.2196-15_2196-2delTTCCTGTTGTTTCA nk +4.6 nk nk
16 c.2204_2211dupAGGCTGAT de novo +4.6 +2.2 moderate
17 c.2230_2232dupATC nk +3.4 +1.7 mild
18 c.2222A>G;p.Y741C de novo +5.3 +2 no
19 c.2233G>A;p.E745K nk +3.5 +1.4 mild Lymphoma
aThe height and OFC measurements are the standard deviations relative to the mean
OFC, occipito-frontal circumference; SD, standard deviations; nk, not known; ALL, acute lymphoblastic leukaemia
Table 1: Summary of EZH2 mutations and associated clinical features
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phenotype (Supplementary Figure 1). We identified one 
recurrent mutation, R684C, which was detected in four 
unrelated individuals. We were able to demonstrate that at 
least two had arisen de novo and therefore independently. 
This suggests that R684 is a mutational hotspot and likely 
reflects the increased mutability of the CpG site at this 
position. We believe the mutations 2230_2232dupATC, 
D664V, and E745K are pathogenic as they occur at highly 
conserved residues and were identified in individuals with 
a clinical diagnosis of Weaver syndrome. Parental samples 
were not available and thus it is possible that these are 
rare polymorphisms. However, analysis of 115 population 
controls through the full EZH2 sequence did not reveal 
either these, or any similar mutations, lending further 
Figure 1: Facial features and height of EZH2 mutation-positive individuals. (a) Typical facial appearance of children with an 
EZH2 mutation and Weaver syndrome. (b) Height distribution of EZH2 mutation-positive individuals relative to the mean UK1990 height 
[22].
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Figure 2: EZH2 structure, mutations and homology. (a) Schematic representation of the protein structure of EZH2 with domains 
and mutations. Missense mutations are represented above the protein and truncating mutations below the protein. (b) Across species 
homology of the EZH2 SET domain demonstrating missense mutations targeting conserved residues. 
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support that they are pathogenic. The full list of EZH2 
sequence variants we identified is given in Supplementary 
Table 2. 
DISCUSSION
EZH2 (Enhancer of Zeste, Drosophila, homolog 
2) encodes the catalytic component of the polycomb 
repressive complex 2 (PRC2), which epigenetically 
regulates chromatin structure and gene expression 
through trimethylation at H3K27 and recruitment of 
DNA methyltransferases, both of which act to repress 
transcription [11, 12]. EZH2 also has critical roles in 
stem cell maintenance and cell lineage determination, 
including osteogenesis, myogenesis, lymphopoiesis 
and hematopoiesis [13]. EZH2 contains a number of 
functional domains and it is noteworthy that the majority 
of the mutations we identified are missense mutations that 
target highly conserved residues within these domains 
(Figure 2). 
Somatic gain-of-function and loss-of-function 
mutations in EZH2 have been reported in haematological 
malignancies [4, 5, 14, 15]. Activating somatic mutations 
at Y646, which increase H3K27 trimethylation, have been 
reported in 22% of diffuse large-cell B-cell lymphomas 
and in 7% of follicular lymphomas [14, 16]. Inactivating 
somatic EZH2 mutations have been reported in myeloid 
neoplasms such as poor prognosis myelodysplasia-
myeloproliferative neoplasms (10-13%), myelofibrosis 
(13%) and various subtypes of myelodysplastic syndromes 
(6%) [4, 5, 15]. 
The mutations we identified in Weaver syndrome 
show considerable overlap with the mutations in myeloid 
malignancies. Indeed, three of the mutations, D664V, 
R684C and Y733X have also been detected as somatically 
acquired mutations in CMML and myelofibrosis [4]. Only 
two of the EZH2 mutation-positive individuals we report 
have developed malignancies; case 8 who carries a de novo 
missense mutation, A682T, in the SET domain, developed 
neuroblastoma and acute lymphoblastic lymphoma, both 
diagnosed at 13 months. Case 19 harbours a missense 
mutation, E745K, in the post-SET domain and developed 
lymphoma at 12 years. However, it should be noted that 
the oldest mutation-positive individual for whom we have 
follow up data is only 27 years old, and little long-term 
clinical data is currently available in Weaver syndrome. 
Given that the myeloid malignancies associated with 
somatic EZH2 mutations usually occur in later life it is 
possible that individuals with Weaver syndrome are at 
increased risk of myeloid and/or other malignancies. 
Although there is overlap of the mutational spectra 
in Weaver syndrome and myeloid malignancies, there are 
also differences. The majority of mutations we identified 
are missense variants. We identified only three truncating 
mutations; all affect the last EZH2 exon and therefore 
may not initiate nonsense mediated RNA decay. By 
contrast, somatic truncating mutations have been reported 
throughout EZH2 [4, 5]. Additionally, germline mutations 
that result in full gene inactivation are predominantly 
truncating mutations that occur throughout the gene, for 
example NSD1 mutations in the overgrowth condition, 
Sotos syndrome [17]. These data suggest that the 
mutations in Weaver syndrome are not acting simply by 
generating haploinsufficiency. Larger, long-term studies 
of Weaver syndrome, together with functional analyses, 
should provide further insights into the nature of causative 
mutations and associated cancer risks. 
There were consistent clinical features amongst the 
19 individuals with EZH2 mutations. Most prominent 
was increased height. The height of all mutation-positive 
individuals was at least two standard deviations above 
the mean and in nine individuals it was greater than four 
standard deviations above the mean (Table 1, Figure 1). 
Increase in head circumference was less dramatic, in 
contrast to Sotos syndrome and the PTEN-associated 
syndromes in which macrocephaly is the more prominent 
and consistent manifestation of overgrowth (Table 1) [6, 
17, 18]. Learning disability was frequent and usually in the 
mild-moderate spectrum, although some individuals had 
no reported learning difficulties. EZH2 mutation-positive 
individuals have a recognisable facial phenotype that 
includes a round face, high broad forehead, high hairline 
and hypertelorism (Figure 1). Although distinctive, indeed 
16 of the 19 individuals we identified were referred with 
a clinical diagnosis of Weaver syndrome, overall the 
clinical characteristics can be relatively subtle and there 
may be considerable under-diagnosis of this condition. 
EZH2 is the second histone methyltransferase 
associated with human overgrowth. Weaver syndrome 
shares many clinical similarities with the overgrowth 
condition, Sotos syndrome, which is due to mutations 
in the histone methyltransferase NSD1 [17]. Moreover, 
EZH2 is part of the PI3K/mTOR pathway which includes 
other genes that have been associated with dysregulated 
growth in humans [19]. For example, a somatic mutation 
in AKT1 causes Proteus syndrome [20] and germline 
PTEN mutations can cause macrocephaly and overgrowth 
[6, 18]. It is also of interest that these pathways were 
not strongly implicated in large-scale, genome-wide 
association studies of height [1]. This suggests that 
common variation in these genes may not contribute to 
human growth regulation and further emphasises the 
importance of studies of rare genetic syndromes in the 
explication of fundamental biological processes. 
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METHODS
Samples
Cases 
Individuals with overgrowth were recruited through 
the Childhood Overgrowth Study. Informed consent 
was obtained from all participants and the research had 
approval from the London Multicentre Ethics Committee, 
(Reference: MREC/01/2/44). A full list of collaborators 
is given in the Supplementary Appendix. Cases were 
included in the EZH2 mutation screening if they had a 
clinical diagnosis of Weaver syndrome or if they had a 
non-specific overgrowth phenotype. Included amongst 
the individuals with Weaver syndrome were five who 
had previously been reported, cases 3, 5, 6, 7, and 17 [3, 
21]. The group with non-specific overgrowth included 
individuals with global overgrowth, where both height and 
head circumference were at least two standard deviations 
above the mean, individuals with isolated macrocephaly 
where the head circumference was at least two standard 
deviations above the mean but height was below two 
standard deviations above the mean and individuals 
with height but not head circumference greater than two 
standard deviations above the mean. For figure 1, the 
height of EZH2 mutation-positive individuals was plotted 
with reference to the mean height which was calculated 
using sex-averaged data from male and female UK1990 
growth charts, which was provided by the Child Growth 
Foundation [22].
Controls
DNA samples from UK controls were from the 
1958 Birth Cohort, an ongoing follow-up of persons born 
in Great Britain in one week in 1958 which included a 
biomedical assessment during 2002-2004 at which blood 
samples and informed consent were obtained for creation 
of a genetic resource http://www.cls.ioe.ac.uk/studies.
asp?section=000100020003.
Exome sequencing
The exome preparation and sequencing for cases 3, 
10 and 16 was performed at Ambry Genetics Corp. (Aliso 
Viejo,CA, USA) using the Agilent SureSelect Human All 
Exon 38 Mb Kit. Each sample was run on two lanes of an 
Illumina Genome Analyzer IIx generating 2x76 bp reads. 
We performed the exome sequencing for case 14 in-house 
using the Illumina Genomic PE Sample Prep Kit (Ilumina, 
San Diego, CA, USA) and the Agilent SureSelect Human 
All Exon 50 Mb Kit. This sample was run on two lanes of 
an Illumina HiSeq Analyzer generating 2x100 bp reads.
Exome sequence analysis
We identified variants in the exomic sequence using 
NextGENe software version 2.10 (SoftGenetics, State 
College, PA, USA). We excluded variants that were 
intronic, synonymous, detected in a known pseudogene, 
recorded in dbSNP or detected in 45 in-house exomes 
from individuals with familial breast cancer that we 
have performed as part of a separate study. To prioritise 
evaluation of variants most likely to be real we first 
included only variants with coverage of at least 15 reads. 
In this final variant set we ran a script to identify genes 
with variants in all four individuals. 
EZH2 mutation analysis
We performed Sanger sequencing of PCR products 
from genomic DNA to confirm the mutations identified 
by exome sequencing, and to mutationally analyse 
the full coding sequence in the overgrowth series. We 
designed PCR primers to amplify the 19 coding exons 
and intron-exon boundaries of EZH2 in 3 multiplex PCR 
reactions (Supplementary Table 1). The PCR was carried 
out using a Qiagen Multiplex PCR kit according to the 
manufacturer’s instructions. Products were sequenced 
with the original PCR primers or internal sequencing 
primers (exons 3 and 20) using the BigDye Terminator 
Cycle Sequencing Kit and an ABI 3730 Genetic Analyzer 
(Applied Biosystems, Foster City, CA,USA). Sequences 
were analyzed using Mutation Surveyor software v3.97 
(SoftGenetics, State College, PA, USA). All mutations 
were confirmed by bidirectional sequencing of a second, 
independently amplified PCR product.
In silico analyses of identified variants
We computed the predicted effects of EZH2 
nonsynonymous variants on protein function using 
PolyPhen [23] and SIFT [24]. All variants (intronic 
and coding) were analysed for their potential effect 
on splicing. Variants were analysed using two splice 
prediction algorithms NNsplice [25] and MaxEntScan, 
[26] via the Alamut software interface (Interactive 
Biosoftware). If both NNsplice and MaxEntScan scores 
were altered by >20% (i.e. a wildtype splice-site score 
decreases and/or a cryptic splice-site score increases) three 
further prediction algorithms were utilised; NetGene2 
[27], HumanSplicingFinder [28] and Genscan [29]. A 
consensus decrease in a wildtype splice-site score and/or 
a consensus increase in a cryptic splice-site score across 
all algorithms was considered indicative of disruption of 
normal splicing. To evaluate the conservation of variants 
we used the HomoloGene system for automated detection 
of homologs among the annotated genes of completely 
Oncotarget 2011; 2:  1127 - 11331132www.impactjournals.com/oncotarget
sequenced eukaryotic genomes. http://www.ncbi.nlm.nih.
gov/homologene/37926.
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